12 Health Care Stocks Moving In Thursday's Pre-Market Session

2/9/23 8:06:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Medical Specialities

Health Care

Get the next $ADXN alert in real time by email

Gainers

Cardiovascular Systems (NASDAQ:CSII) shares moved upwards by 48.4% to $19.75 during Thursday's pre-market session. The market value of their outstanding shares is at $827.1 million. The company's, Q2 earnings came out yesterday.
AnPac Bio-Medical Science (NASDAQ:ANPC) stock rose 25.93% to $11.8. The company's market cap stands at $24.0 million.
Genetic Technologies (NASDAQ:GENE) shares rose 22.6% to $1.79. The company's market cap stands at $27.5 million.
Ontrak (NASDAQ:OTRKP) stock increased by 14.28% to $1.92.
Organovo Holdings (NASDAQ:ONVO) stock rose 12.37% to $2.18. The market value of their outstanding shares is at $18.9 million.
Addex Therapeutics (NASDAQ:ADXN) shares increased by 9.55% to $1.49. The company's market cap stands at $28.6 million.

Losers

Tivic Health Systems (NASDAQ:TIVC) stock fell 51.0% to $0.24 during Thursday's pre-market session. The company's market cap stands at $2.3 million.
Revelation Biosciences (NASDAQ:REVB) shares fell 27.99% to $3.86. The market value of their outstanding shares is at $2.5 million.
Creative Medical Tech (NASDAQ:CELZ) stock decreased by 13.59% to $0.9. The company's market cap stands at $12.6 million.
Sio Gene Therapies (NASDAQ:SIOX) shares fell 12.54% to $0.4. The market value of their outstanding shares is at $29.3 million.
VistaGen Therapeutics (NASDAQ:VTGN) stock decreased by 12.37% to $0.16. The company's market cap stands at $35.7 million. The company's, Q3 earnings came out 2 days ago.
Globus Medical (NYSE:GMED) shares decreased by 11.61% to $68.03. The company's market cap stands at $6.7 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Get the next $ADXN alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ADXN
$ANPC
$CELZ
$CSII

Company	Date	Price Target	Rating	Analyst
Globus Medical Inc. $GMED	1/30/2026	$112.00	Hold → Buy	Needham
Globus Medical Inc. $GMED	1/27/2026	$110.00	Buy	TD Cowen
Vistagen Therapeutics Inc. $VTGN	12/17/2025	$0.90	Buy → Hold	Jefferies
Vistagen Therapeutics Inc. $VTGN	12/17/2025		Buy → Hold	Maxim Group
Vistagen Therapeutics Inc. $VTGN	12/17/2025		Outperform → Mkt Perform	William Blair
Vistagen Therapeutics Inc. $VTGN	12/17/2025	$1.00	Buy → Hold	Stifel
Globus Medical Inc. $GMED	11/7/2025	$93.00	Hold → Buy	Truist
Globus Medical Inc. $GMED	11/7/2025	$91.00	Neutral → Buy	BofA Securities

More analyst ratings

$ADXN
$ANPC
$CELZ
$CSII
Press Releases

Fastest customizable press release news feed in the world

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 46th Annual TD Cowen Healthcare Conference. Vistagen's President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 2, 2026, at 3:50 p.m. Eastern Time. A replay of the webcast will be archived and available following the event through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical com

2/25/26 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for the quarter was $140.6 million.GAAP diluted earnings per share ("EPS") was $1.03, an increase of 442.6%. Non-GAAP diluted EPS was $1.28, an increase of 52.1%. Full Year

2/24/26 4:15:00 PM ET

Medical/Dental Instruments

Health Care

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

2/12/26 4:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$ADXN
$ANPC
$CELZ
$CSII
Leadership Updates

Live Leadership Updates

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

12/1/25 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Medical/Dental Instruments

Vistagen Appoints Paul Edick to its Board of Directors

Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

10/29/25 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

10/22/25 2:00:00 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

$ADXN
$ANPC
$CELZ
$CSII
Financials

Live finance-specific insights

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for the quarter was $140.6 million.GAAP diluted earnings per share ("EPS") was $1.03, an increase of 442.6%. Non-GAAP diluted EPS was $1.28, an increase of 52.1%. Full Year

2/24/26 4:15:00 PM ET

Medical/Dental Instruments

Health Care

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

2/12/26 4:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-

2/12/26 4:30:00 PM ET

Medical/Dental Instruments

Health Care